DOSSIER · 13F-HR · Q1 2026

Rosalind Advisors, Inc.

$249M in tracked AUM across 38 positions as of Q1 2026.

RA
CIK 0001622627 · last filed Mar 31, 2026
Total AUM
$249M
as of Q1 2026
Holdings
38
positions
Whale Score
64
64
tracked
Activity
no data
changes this Q
AI Analysis · Q1 2026
Comprehensive SEC 13F Analysis: Rosalind Advisors, Inc.
Portfolio Overview

Rosalind Advisors, Inc. manages a concentrated, high-conviction portfolio totaling approximately $227.3 million across 31 holdings. The firm employs a specialized investment strategy focused almost exclusively on the healthcare and biotechnology sectors, characterized by high-risk, high-reward opportunities often found in small-cap and micro-cap companies. The portfolio experienced a growth of +7.8% in ...

The portfolio is highly concentrated, with the top ten positions accounting for approximately 71.5% of the total assets. This top-heavy structure suggests that the firm's performance is heavily reliant on the success of a select number of core convictions. The strategy appears to be long-biased, targeting companies with specific clinical catalysts or late-stage drug development pipelines.

Key Holdings

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
DCTH
DELCATH SYSTEMS, INC.
$31M3.3M12.3%
02
XERS
XERIS BIOPHARMA HOLDINGS INC
$19M3.2M7.5%
03
FENC
FENNEC PHARMACEUTICALS INC
$18M2.9M7.2%
04
SVRA
SAVARA INC
$17M3.2M7.0%
05
PCVX
VAXCYTE INC
$17M290K6.8%
06
EYPT
EYEPOINT PHARMACEUTICALS INC
$13M1.0M5.4%
07
XFOR
X4 PHARMACEUTICALS INC
$13M3.2M5.3%
08
VOR
VOR BIOPHARMA INC
$12M700K5.0%
09
M68830112
MEDIWOUND LTD
$12M749K4.8%
10
VSTM
VERASTEM INC
$11M2.1M4.6%

Filing history

2026Q1Mar 31
$249M 12.5%
38 positionsView →
2025Q4Dec 31
$285M 25.2%
42 positionsView →
2025Q3Sep 30
$227M 7.8%
31 positionsView →
2025Q2Jun 30
$211M 21.0%
37 positionsLocked
2025Q1Mar 31
$174M 10.9%
27 positionsLocked
2024Q4Dec 31
$196M 25.2%
40 positionsLocked
2024Q3Sep 30
$156M 20.2%
33 positionsLocked
2024Q2Jun 30
$130M 21.4%
40 positionsLocked
2024Q1Mar 31
$107M 11.9%
34 positionsLocked
2023Q4Dec 31
$121M
30 positionsLocked